echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Jingfeng Medicine Tirofiban Hydrochloride and Sodium Chloride Injection Passed the Consistency Evaluation

    Jingfeng Medicine Tirofiban Hydrochloride and Sodium Chloride Injection Passed the Consistency Evaluation

    • Last Update: 2021-04-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On April 6, Jingfeng Pharmaceutical issued an announcement stating that recently, its subsidiary Guizhou Jingfeng Injection Co.


    Tirofiban Hydrochloride Sodium Chloride Injection is mainly used for adult patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) who have ECG changes and/or elevated myocardial enzymes within 12 hours of the last chest pain onset , To prevent early myocardial infarction.


    Tirofiban is a platelet glycoprotein IIb/IIIa receptor antagonist.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.